Hyanek J, Kozak L, Hrabincova E, Trnka V, Kobilkova J, Dolezal A, Soukup K, Zeman J, Stastna S, Vadurova L, Krijt J, Viletova H, Cervena M, Paterova T
Institute for Inherited Metabolic Disorders, Obstetric and Gynaecologic Clinic of 1st Medical School Charles University Prague, Czech Republic.
Bratisl Lek Listy. 2004;105(9):291-8.
The increased level of phenylalanine (Phe) in maternal blood--hyperphenylalaninemia (mHPA) has a detrimental effect on the early development of healthy foetus (1965). The toxic effect causes spontaneous abortion or retards intrauterine growth, skeletal malformation, cardiac anomalies can appear. However the most frequent are microcephaly, mental retardation and hypotrophy.
Simultaneously with the introduction of obligatory "Newborn Screening Program" in CR also the facultative screening for mHPA was introduced ("Maternal Hyperphenylalaninemia Preventive Screening Program"). Since 1975 till now 222,990 healthy pregnant women (16-47 yrs) from city Prague and its area (cca 2 mil. inh.) have been screened for increased Phe in blood by Efron's chromatographic screening test (1964); Phe cut off value: 240 micromol/l. Nonfasting venous blood has been taken in 2nd-3rd month of pregnancy during the first antenatal visit. All positive cases have been verified with quantitative Phe estimation on amino acid analyzer incl. pterines analysis in urine. For differentiation of detected mHPAs the Güttler's scheme (1980) has been used. Mutations for Phe-hydroxylase gene analyzed by restriction enzyme digestion after Guldberg (1994).
The average incidence of mHPA detected at the beginning of pregnancy was found 1:8675. The major part (65.3%) of all detected mHPA belongs to mild or moderate form of phenylketonuria (PKU) with most frequent PAH gene mutations R408W, Y414C, IVS11 nt8g-a, R158Q, IVS12ntlg-a and R261Q. 19.2% corresponds to atypical or classical PKU with prevailing mutation R408W. Only in 15.3% were detected non-PKU (persistent HPA) with mutations R408W, Y414C, IVS12ntlg-a, IV11nt8g-a and A403V. 28 offsprings born from pregnancies on low-phenylalanine diet (LPD) introduced at least 2 months before the conception and during the whole pregnancy show normal psychomotoric development. In 7 offsprings without LPD or after delayed introducing or on PLD or badly monitored showed malformations (microcephaly, hypotrophy, skeletal malformations) or died.
Relatively high incidence of mHPA detected in healthy population of pregnant women of Prague area differs from findings of Buist (1989) or Levy (1994) from American pregnant women screened for mHPA from umbilical blood. We consider that screening performed at the beginning of pregnancy from nonfasting venous blood is more effective compared to umbilical blood from two reasons: the Phe level in maternal blood is increased during first trimester of pregnancy due to succing effect of placenta in comparison to decreased Phe level at the end of labour. Umbilical blood for screening of mHPA is not quite suitable to detect the atypical or mild forms of Phe disturbances which prevailed in our Slavonic population of pregnant women. (Tab. 5, Fig. 7, Ref. 16.)
母体血液中苯丙氨酸(Phe)水平升高——高苯丙氨酸血症(mHPA)对健康胎儿的早期发育具有有害影响(1965年)。这种毒性作用会导致自然流产或阻碍子宫内生长,出现骨骼畸形、心脏异常。然而,最常见的是小头畸形、智力发育迟缓及发育不良。
在捷克共和国(CR)推行强制性“新生儿筛查计划”的同时,也引入了针对mHPA的选择性筛查(“母体高苯丙氨酸血症预防性筛查计划”)。自1975年至今,已对来自布拉格市及其周边地区(约200万居民)的222,990名健康孕妇(16 - 47岁)进行了埃弗隆色谱筛查试验(1964年),以检测血液中升高的苯丙氨酸;苯丙氨酸临界值:240微摩尔/升。在首次产前检查时,于妊娠第2 - 3个月采集非空腹静脉血。所有阳性病例均通过氨基酸分析仪进行苯丙氨酸定量测定加以验证,包括尿液中蝶呤分析。为区分检测出的mHPA,采用了古特勒方案(1980年)。按照古德伯格(1994年)的方法,通过限制性酶切分析苯丙氨酸羟化酶基因的突变。
在妊娠初期检测到的mHPA平均发病率为1:8675。所有检测出的mHPA中,大部分(65.3%)属于轻度或中度苯丙酮尿症(PKU),最常见的苯丙氨酸羟化酶(PAH)基因突变有R408W、Y414C、IVS11 nt8g - a、R158Q、IVS12ntlg - a和R261Q。19.2%对应非典型或经典PKU,主要突变是R408W。仅15.3%检测为非PKU(持续性HPA),突变有R408W、Y414C、IVS12ntlg - a、IV11nt8g - a和A403V。28名在受孕前至少2个月及整个孕期采用低苯丙氨酸饮食(LPD)的孕妇所生后代,其精神运动发育正常。7名未采用LPD或引入延迟、或采用普通蛋白饮食(PLD)或监测不佳的孕妇所生后代出现畸形(小头畸形、发育不良、骨骼畸形)或死亡。
在布拉格地区健康孕妇群体中检测到的mHPA发病率相对较高,这与布伊斯特(1989年)或利维(1994年)对美国孕妇脐血中mHPA筛查的结果不同。我们认为,在妊娠初期从非空腹静脉血进行筛查比脐血筛查更有效,原因有两点:与分娩末期苯丙氨酸水平降低相比,由于胎盘的摄取作用,母体血液中苯丙氨酸水平在妊娠头三个月会升高。用于筛查mHPA的脐血不太适合检测在我们斯拉夫孕妇群体中占主导的非典型或轻度苯丙氨酸紊乱形式。(表5,图7,参考文献16)